193 related articles for article (PubMed ID: 23901069)
1. Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3).
Baek AE; Kanthi Y; Sutton NR; Liao H; Pinsky DJ
FASEB J; 2013 Nov; 27(11):4419-28. PubMed ID: 23901069
[TBL] [Abstract][Full Text] [Related]
2. cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression.
Liao H; Hyman MC; Baek AE; Fukase K; Pinsky DJ
J Biol Chem; 2010 May; 285(19):14791-805. PubMed ID: 20178980
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
Shakur Y; Fong M; Hensley J; Cone J; Movsesian MA; Kambayashi J; Yoshitake M; Liu Y
Cardiovasc Drugs Ther; 2002 Sep; 16(5):417-27. PubMed ID: 12652111
[TBL] [Abstract][Full Text] [Related]
5. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Alyonycheva TN; Safier LB; Hajjar KA; Posnett DN; Schoenborn MA; Schooley KA; Gayle RB; Maliszewski CR
J Clin Invest; 1997 Mar; 99(6):1351-60. PubMed ID: 9077545
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.
Hanson MS; Stephenson AH; Bowles EA; Sridharan M; Adderley S; Sprague RS
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H786-93. PubMed ID: 18586889
[TBL] [Abstract][Full Text] [Related]
7. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
Zhang W; Ke H; Colman RW
Mol Pharmacol; 2002 Sep; 62(3):514-20. PubMed ID: 12181427
[TBL] [Abstract][Full Text] [Related]
8. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Wang S; Cone J; Fong M; Yoshitake M; Kambayashi Ji ; Liu Y
J Cardiovasc Pharmacol; 2001 Nov; 38(5):775-83. PubMed ID: 11602824
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
10. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment.
Drosopoulos JH; Broekman MJ; Islam N; Maliszewski CR; Gayle RB; Marcus AJ
Biochemistry; 2000 Jun; 39(23):6936-43. PubMed ID: 10841775
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells.
Ota H; Eto M; Kano MR; Ogawa S; Iijima K; Akishita M; Ouchi Y
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1634-9. PubMed ID: 18556572
[TBL] [Abstract][Full Text] [Related]
12. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells.
Imai M; Kaczmarek E; Koziak K; Sévigny J; Goepfert C; Guckelberger O; Csizmadia E; Schulte Am Esch J; Robson SC
Biochemistry; 1999 Oct; 38(41):13473-9. PubMed ID: 10521254
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.
Gayle RB; Maliszewski CR; Gimpel SD; Schoenborn MA; Caspary RG; Richards C; Brasel K; Price V; Drosopoulos JH; Islam N; Alyonycheva TN; Broekman MJ; Marcus AJ
J Clin Invest; 1998 May; 101(9):1851-9. PubMed ID: 9576748
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury.
Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC
Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235
[TBL] [Abstract][Full Text] [Related]
15. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Nakamura K; Ikomi F; Ohhashi T
J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
[TBL] [Abstract][Full Text] [Related]
16. Substitution of His59 converts CD39 apyrase into an ADPase in a quaternary structure dependent manner.
Grinthal A; Guidotti G
Biochemistry; 2000 Jan; 39(1):9-16. PubMed ID: 10625474
[TBL] [Abstract][Full Text] [Related]
17. The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms.
Choi HI; Kim DY; Choi SJ; Shin CY; Hwang ST; Kim KH; Kwon O
J Dermatol Sci; 2018 Jul; 91(1):60-68. PubMed ID: 29678305
[TBL] [Abstract][Full Text] [Related]
18. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.
Dzhandzhugazyan KN; Kirkin AF; thor Straten P; Zeuthen J
FEBS Lett; 1998 Jul; 430(3):227-30. PubMed ID: 9688544
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells.
Hashimoto A; Tanaka M; Takeda S; Ito H; Nagano K
PLoS One; 2015; 10(7):e0132835. PubMed ID: 26181635
[TBL] [Abstract][Full Text] [Related]
20. Deletion of cd39/entpd1 results in hepatic insulin resistance.
Enjyoji K; Kotani K; Thukral C; Blumel B; Sun X; Wu Y; Imai M; Friedman D; Csizmadia E; Bleibel W; Kahn BB; Robson SC
Diabetes; 2008 Sep; 57(9):2311-20. PubMed ID: 18567823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
